That is rare but crucial extra-intestinal complications during an exacerbation in patients with inflammatory bowel disease (IBD)-ulcerative colitis (UC) and Crohn's disease. 1)2) Cardiac complications occur particularly with UC, 2) and few cases reported patients with various manifestation from fulminant myocarditis to mild form. [3] [4] [5] Control of the underlying diseases is often associated with resolution of myocarditis and prevention of recurrence.
Introduction
138 bpm. Initial echocardiography showed dilated left ventricular (LV) dimension and decreased LV ejection fraction (EF: 33%) with preserved LV tissue velocities (Fig. 1 , Supplementary movie 1). We decided to apply extracorporeal membrane oxygenation (ECMO) for cardiac rest under impression of acute myocarditis because her coronary angiography showed normal coronary arteries (Fig. 2) in combination with global hypokinesia of LV. Follow up echocardiography performed the following day (Fig. 3 , Supplementary movie 2) showed much depressed LV systolic function (EF: 10%) and myocardial tissue velocities (E': 10 → 3 cm/s, S': 6 → 2 cm/s). The 7th day after ECMO, massive hematochezia was occurred even with maintenance of corticosteroid (methylprednisolone 33 mg). Emergent sigmoidoscopy revealed diffuse maroon colored blood oozing from inflamed mucosa of transverse colon without discernable specific bleeding focus. Increased LV wall thickness (8 → 13 mm) and still depressed LV performance (EF: 16%, E': 2 cm/s, S': 3 cm/s) detected by echocardiography (Fig. 4, Supplementary movie 3 We report a case of successfully treated acute fulminant myocarditis induced by ulcerative colitis with extracorporeal life support and infliximab. Myocarditis is a rare but crucial complication during an exacerbation of inflammatory bowel disease. In our case, we applied extracorporeal membrane oxygenation (ECMO) for cardiac rest under impression of acute myocarditis associated with ulcerative colitis, and added infliximab for uncontrolled inflammation by corticosteroid. As a result, our patient was completely recovered with successful weaning of ECMO.
bilized without further bleeding and echocardiography (Fig. 5 , Supplementary movie 4) showed improved LV systolic function (EF: 16 → 60%) and myocardial tissue velocities (E': 3 → 5 cm/s, S': 2 → 7 cm/s). Last echocardiography (Fig. 6 , Supplementary movie 5) showed normal LV wall thickness (11 → 8 mm), EF (65%), and myocardial tissue velocities (E': 12 cm/s, S': 10 cm/s). In addition, cardiac biomarkers (CK-MB: 11.4 → 8.4 → 5.8 → 1.4 ng/mL, troponin I: 0.512 → 0.298 → 0.099 → 0.025 ng/mL), ECG, and CXR were all normalized (Fig. 7) . Now she is stable and followed regularly on outpatient basis with maintenance of low dose steroid.
Discussion
UC is known to be a severe disease with many extra-colonic manifestations, such as skin involvement, rheumatic problems, and ocular complications.
2) Here we present a young female patient with UC and fatal cardiac complication that were not resolved with corticosteroids.
In our patient, acute myocarditis was developed presenting dyspnea and elevated cardiac biomarkers during exacerbation of 
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UC in the maintenance of corticosteroid. We rapidly decided to apply ECMO for cardiac rest even her LV EF was not severely depressed and also with preserved LV myocardial tissue velocities. As a result, our decision was not so impetuous because echocardiography performed the very next day revealed severely depressed LV EF and myocardial tissue velocities. Unexpected Therefore we apply infliximab to control underlying bowel inflammation and acute management for UC. Follow up echocardiography after infusion infliximab, result showed improved LV abrupt hematochezia was occurred despite of maintenance of corticosteroid (methylprednisolone 33 mg). Not only sigmoidoscopy showed uncontrolled inflammation of transverse colon, echocardiography also revealed increased thickness of myocar- 
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systolic function (EF: 16 → 60%) and myocardial tissue velocities (E': 3 → 5 cm/s, S': 2 → 7 cm/s). Infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha used to treat autoimmune diseases. Although this agent has various adverse effects, some life-threatening, common to drugs in the class of immunosuppressants, patients with UC with treatment of infliximab was shown effective inflammation control. 8) In conclusion, we report a young female patient with fulminant myocarditis associated with UC successfully treated with ECMO and infliximab. Serial follow up of echocardiography and early decision of applying ECMO were particularly essential for management in our patient. Control of underlying disease might be helpful to improve cardiac function, in case of acute myocarditis due to underlying IBD. 
